Fig. 1

Claudin-2 expression is sharply downregulated in human renal clear cell carcinoma and associates with poor patient survival: (a) Claudin-2 transcriptome analysis in TCGA database [*P < 0.03 (stage-1Vs stage-4), ****P < 0.00006 (Stage-2 Vs stage-4,**P < 0.0020212 (Stage-3 Vs Stage-4) (b) Represent claudin-2 proteomic expression profile based on individual cancer stage of RCC in CPTAC (Clinical Proteomic Tumor Analysis Consortium) database (Normal Vs grade 1 P < 5.05E-4; Normal Vs grade 2 P < 1.76E-22; Normal Vs grade 3 P < 1.16E-16; Normal Vs grade 4 P < 1.53E-5); (c) Kaplan-Meir analysis to determine overall patient survival in relation with claudin-2 expression. The red and blue colors indicate high and low claudin-2 expression, respectively (***P < 0.0012); (d) Representative images of immunohistochemistry of claudin-2 using RCC patient’s TMA (N = 207); (e) Representative image of the immuno-histochemical analysis of claudin-2 expression in archived renal cancer surgical specimen with adjacent normal tissue; (f) Represent the intensity score of claudin-2 in patient samples. Data is presented as mean + sem. Statistical significance was determined by 1-way ANOVA and post hoc Tukey’s test for pairwise comparison. ***P < 0.001. Scale bar = 50 μM